CAS: 654-47-7; 1-Fluoro-2-(Methylsulfonyl)Benzene

上下游产品

CAS号655-20-9 2-氟茴香硫醚 | CAS号462-06-6 氟苯 | CAS号124-63-0 甲基磺酰氯 | CAS号7143-01-3 甲基磺酸酐

📜2-氟茴香硫醚置于氧气体系中,化学反应 20.0H,以78%的收率获得产物2-氟苯基甲基砜
参考文献:通过o2 / Air溶剂促进的硫化物氧化,芳基砜和亚砜的可切换合成.
标题:通过o2 / Air溶剂促进的硫化物氧化,芳基砜和亚砜的可切换合成.
摘要:提出了一种通过硫化物氧化合成芳基砜和亚砜的实用且可转换的方法.使用o 2 /空气作为末端氧化剂和氧气源,通过反应温度可以简单地控制产物的化学选择性.广泛的底物范围,容易实现的克级生产以及简化的硫化物氧化系统使该策略具有吸引力和价值.
DOI:10.1021/acs.Orglett.9B03192

专利信息

专利号:US-2003232996-A1
优先权日:2001-04-20
标题:Regioselective synthesis of 3,4-di{(carboclyl or heterocyclyl)thiophenes
发明人：BROWN DAVID L; LUDWIG CINDY L
摘要:A novel process for preparing 3,4-di(carbocyclyl or heterocyclyl)thiophenes comprising reacting a compound of Formula IV with a ring cyclizing reagent to form the compound of Formula V to yield a compound of Formula V wherein R 1 , R 2 and R 3 are as defined in the specification.

专利号:US-6600052-B1
优先权日:2000-04-25
标题:Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
发明人：BROWN DAVID L; LUDWIG CINDY L
权利人:PHARMACIA CORP
摘要:A novel process for preparing 3,4-di(carbocyclyl or heterocyclyl)thiophenes comprising reacting a compound of Formula IV:with a ring cyclizing reagent to form the compound of Formula V to yield a compound of Formula V:wherein R1, R2 and R3 are as defined in the specification.

专利号:EP-1276736-A2
优先权日:2000-04-25
标 题:Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes

专利号:WO-0181333-A2
优先权日:2000-04-25
标 题 :Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes

专利号:WO-2021018023-A1
优先权日:2019-08-01
标题:Small molecule glp-1 receptor modulator
发明人：XIE FANG; YU GUANGXIA; ZHANG SHUJUAN
权利人:THE TITAN LEADING MED TECH INC
摘要:The present invention provides a new compound for modulating a Glucagon-like peptide-1 (GLP-1) receptor, and a synthesis method therefor and a pharmaceutical use thereof. This kind of compound has an obvious agonistic effect on the GLP-1 receptor, but does not have an obvious binding effect on hERG, and therefore, it is indicated that the compound has a low risk of cardiotoxicity. The compound of the present invention can be used alone as a treatment medication for type II diabetes, or be used in combination with a polypeptide GLP-1 receptor agonist such as liraglutide, or be used in combination with the treatment medication for type II diabetes of other mechanisms.